New data presented at this year’s American Society of Hematology shows the mechanism of action by which cell therapy derived from the human placenta treats radiation-induced bone marrow damage. The findings will be published online in the December 3, 2015 supplemental volume of Blood, a peer-reviewed medical journal published by ASH.
Placental cells could potentially be used to treat stroke or other injuries to the nervous system attributable to low oxygen or glucose levels according to newly published study.
For an organ that only functions for nine months, the placenta has been taking the science world by storm. One company that is banking on the therapeutic powers of the placenta is Pluristem Therapeutics, a key player in the regenerative medicine space.
Preliminary studies point to adherent stromal cells derived from human placenta appear promising as a readily available cell source to aid tendon healing and regeneration.
The findings of the published study suggest that the intramuscular treatment with placenta-based cell therapies may serve as a highly effective “off the shelf” therapy to mitigate Acute Radiation Syndrome (ARS).
According to findings from an early preclinical study led by Brett Mitchell, PhD, an Associate Professor of Internal Medicine in the Cardiovascular Research Institute (CVRI) at Texas A&M University College of Medicine, there is evidence that administrating placenta-derived cells may help reverse the symptoms associated with preeclampsia in a matter of days after dosing with no harmful effects to mother or baby.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right